This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
“My UC is fine, honestly. I don't really go to the toilet much more than normal. Maybe 2–4 times a day total? I try to keep it to less than that as I'm too busy with work. I love my job, and my media clients; we had 3 workshops with them last week and we’re gearing up for a really intense period. So, of course I’m run down at the end of the day, but who isn’t? No one said having a chronic disease was easy! Of course you have to make compromises.”
Recently, Júlia has had a recurrence of some UC symptoms (abdominal pain; diarrhoea), which have worried her that she may have to step away from client work – work she really values. To manage this, she has started fasting11 and avoiding certain foods and social situations involving food in an attempt to reduce her number of daily stools. This has led to fatigue and light-headedness during the working day.
Can you think of a patient like Júlia, whose resilience is impacting their quality of life?
Initially prescribed oral 5-ASAs. Corticosteroids (CSs) were added after a series of flares, but Amadou became CS dependent. He continued with oral 5-ASAs, and azathioprine was added to wean off CSs. He achieved clinical remission, but requested to be taken off azathioprine after ~3 years because, similar to when he was CS dependent, he experienced repeated infections. Amadou then continued with oral 5-ASAs, with topical 5-ASAs being prescribed ~1 year ago to treat persistent symptoms. He is currently not prescribed with CSs.
“I’m a bit tired and stressed out, but otherwise good. Thanks for recommending the patient organisation. Their website is very insightful and convinced me that I'm on the right treatment. I’m doing OK on my new meds. Football? No, I had to quit the team unfortunately, I’ve had a busy period at work, and I was finding it hard to keep up with the demands of both work and football.”
Amadou has not disclosed to his doctor that he is still experiencing abdominal pain on his current treatment. He is highly health literate and is aware this means he will likely require advanced therapy, but he has downplayed his symptoms because of his safety concerns. Amadou is highly stressed because of his situation. The persistent symptoms are affecting his social life, causing him to quit the football team he was captain of, something he took great pride in.
What questions would you ask to better understand a patient's experience with UC?
“A lot has happened since we last spoke. I’ve sadly left the band. I can’t keep up with the live shows these days. Instead, I’ve started music lessons from home. It’s definitely a step down from the stage, but working from home is a better fit for me these days. My UC is OK, I think. I’ve had no bleeding since we started the steroid foam. It would be nice to know a bit more about my type of UC – isolated proctitis, I think it’s called?”
Live music has become increasingly difficult for Markus. Having to apply the topical foam backstage before a gig was neither convenient nor a pleasant experience. What’s more, he started to experience troublesome symptoms more frequently. Markus is embarrassed to talk about it, but he has experienced accidents at work during gigs due to sudden onset of bowel urgency. This has negatively impacted his ability to work, because he always needs to know where the nearest toilet is. Despite his passion for live music, he felt he could only function fully within the comfort of his own home, so he quit the band and started teaching music from home instead.
Do you know any patients with UC who have shaped their life around their disease?
The prevalence and impact of uncontrolled UC
Resources to help look behind “OK” for patients’ UC
Click here for Xeljanz®(tofacitinib citrate) Prescribing information and click here for VELSIPITY▼ (etrasimod) Prescribing Information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.